1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Stefanie S. Schalm, Tom Dineen, Sangbin Lim, C.W. Park, John Hsieh, Rich Woessner, Z. Zhang, Kevin Wilson, Meredith S. Eno, Douglas Wilson, Brett Williams, John Campbell, Chris De Savi, Faith Stevison, Caitlin Utt, Timothy Guzi, Marion Dorsch, Klaus P. Hoeflich, B.C. Chul Cho
Topics & Concepts
T790MOsimertinibMedicineCancer researchKinaseMutantEpidermal growth factor receptorCancerLung cancerErlotinibOncologyChemistryGefitinibInternal medicineBiochemistryGeneLung Cancer Treatments and MutationsCancer therapeutics and mechanismsColorectal Cancer Treatments and Studies